Patents by Inventor Enzon Pharmaceuticals, Inc.

Enzon Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGOMERIC COMPOUNDS FOR THE MODULATION OF HIF-1A EXPRESSION
    Publication number: 20130116309
    Abstract: Oligonucleotides directed against the hypoxia-inducible factor-1? (HIF-1?) gene are provided for modulating the expression of HIF-1?. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding the HIF-1?. Methods of using these compounds for modulation of HIF-1? expression and for the treatment of diseases associated with the hypoxia-inducible factor-1? are provided. Examples of diseases are cancer and pre-eclampsia. The oligonucleotides may be composed of deoxyribonucleosides, a nucleic acid analogue, or Locked Nucleic Acid (LNA) or a combination thereof.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 9, 2013
    Applicants: Santaris Pharma A/S, Enzon Pharmaceuticals, Inc.
    Inventors: Enzon Pharmaceuticals, Inc., Santaris Pharma A/S